An analysis of approved drugs that emerged from licensing deals over nearly a decade may upend conventional thinking. Long considered a drug development graveyard, alliances for compounds that treat CNS disorders were more likely to result in drug approvals than any other therapeutic category. Not as surprising: nearly half of the deals that resulted in an approved product featured up-front payments below $25 million, but the odds of developing an approved drug increased as up-front payments became larger.
There's a 1-in-10 chance that any drug candidate in Phase I will be approved by the FDA. Those chances get...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?